Seoul Economic Daily EnglishCodex · 实盘不做把握 5/10不做原因:已被定价
北京时间·🕒 发布 16:16:27(首尔 17:16)·⟳ 抓取 16:26:33 +10m06s·⚡ 决策 09-01 16:33:57 +7m24s·56.3 天前
Bukwang Pharmaceutical子公司Union Korea Pharm法院重整程序正式终结
事件方向偏正面，但8月14日已披露申请终结重整并给出核心债务清偿数字，9月1日韩股盘中已出现显著同向上涨和VI触发，当前为韩国盘后且缺少可用真实报价形成可执行限价，短线剩余edge不足。
📄 原文Seoul Economic Daily English↗ 原文
Bukwang Unit Union Korea Pharm Exits Court Rehabilitation
Court rehabilitation proceedings for Union Korea Pharm, a subsidiary of Bukwang Pharmaceutical, have formally concluded…
不做 Bukwang Pharmaceutical（003000.KS）
事件偏正面但属于8月14日前置披露后的程序落地，9月1日盘中已显著上涨并触发VI，当前韩国盘后不可成交且缺少可量化利润增量，不追盘后明牌。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Bukwang Pharmaceutical对Union Korea Pharm的300亿韩元注资和债权清偿推动法院终结重整，基本面上降低子公司财务不确定性并支持委托生产协同；但核心交易线索在8月14日已公开，9月1日盘中股价已最高出现约9%级别反应，且收盘后无法即时成交，未能量化对Bukwang收入/利润的新增占比，因此不追盘后明牌。
消息传播链
- 8月14日已报道Union Korea Pharm申请终结重整，并披露300亿韩元注资、约292亿韩元债权中99.7%已偿还。
- 公司官网披露首尔回生法院于8月31日决定终结Union Korea Pharm重整程序。
- 韩文财经媒体报道重整程序结束、负债率改善和委托生产协同。市场反应:报道页显示Bukwang Pharmaceutical为4380韩元、涨4.66%。
- CBC称Bukwang Pharmaceutical盘中13:03报4575韩元、涨9.31%，12:13触发静态VI并于12:15解除。市场反应:盘中已显著上涨，说明事件在韩国收盘前已有交易反应。
关键理由
- 重整终结消除了Union Korea Pharm的法院程序约束，子公司负债率从资不抵债改善至40%区间。
- Bukwang已开始将复合Pazyme Double等药品委托给Union Korea Pharm生产，存在制造协同和合并收入扩张可能。
- 量级上，300亿韩元注资和292.01亿韩元债权清偿是已披露资本动作，但本次新增可触达收入与利润增量未披露，无法估算对Bukwang市值和盈利的弹性。
主要风险
- 核心债务清偿和申请终结重整在2026-08-14已被媒体披露，本次法院裁定更偏程序落地，预期差有限。
- 9月1日盘中已有明显同向上涨和VI触发，盘后再追容易面对高开低走和T+交易时段错配。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-14 · 影响 weakens
申请终结和99.7%债务清偿核心事实两周前已公开，削弱本次新增预期差。
检索:Bukwang Pharmaceutical Union Korea Pharm filed to conclude rehabilitation August 14 2026 debt repayment 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-09-01 · 影响 weakens
事件当日韩股盘中已大涨并触发VI，收盘后再追的price-in风险高。
检索:Bukwang Pharmaceutical shares surge September 1 2026 VI triggered 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-09-01 · 影响 weakens
媒体和公司表述仅称扩大销售、制造协同并推动Union Korea Pharm扭亏，未披露可量化收入或利润增量。
检索:Bukwang Pharmaceutical Union Korea Pharm synergy sales profit turnaround 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使仓位和止盈止损无法可靠标定；结合已反应和盘后不可成交，最终改为不做。
方向:缺少同市场、同机制且有干净首发锚的上市母公司子公司重整终结先例，方向只能由本事件基本面判断为偏正面。
涨幅量级:没有足够高相似先例校准涨幅；盘中约9%反应更像事件落地后的即时重定价，不能作为继续追高依据。
形态:未取得足够样本判断是否系统性见光死；但本事件为程序性落地且已有8月14日前置信息，追高风险偏高。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,034 字
Court rehabilitation proceedings for Union Korea Pharm, a subsidiary of Bukwang Pharmaceutical, have formally concluded.
Bukwang Pharmaceutical (003000) said on the 1st that the Seoul Rehabilitation Court decided on the 31st to terminate the rehabilitation proceedings for Union Korea Pharm under the Debtor Rehabilitation and Bankruptcy Act.
Bukwang Pharmaceutical had paid a total of 30 billion won ($21.6 million) for new shares on May 27, becoming the largest shareholder of Union Korea Pharm. Union Korea Pharm subsequently carried out changes to creditor rights and repayment of rehabilitation claims under its rehabilitation plan. Of about 29.2 billion won in claims due for repayment this year, the company repaid most of the total, excluding some unconfirmed claims. The remaining unpaid balance stands at 76 million won. The company filed for termination of the rehabilitation proceedings with the Seoul Rehabilitation Court on the 14th of last month.
Union Korea Pharm's financial structure has improved significantly since the acquisition. According to Bukwang Pharmaceutical, the company's debt-to-equity ratio has fallen to the 40% range from a state of impaired capital before the acquisition. Past unpaid trade payables, borrowings and bonds with warrants have all been repaid, the company said.
Cooperation between the two companies has already begun. Bukwang Pharmaceutical outsourced drug production to Union Korea Pharm and shipped the digestive medicine Bokhap Pazyme Double Tablet in June. Hardcal Chewable Tablet and Hardcal Chewable Easy Tablet, over-the-counter thyroid and endocrine drugs, will also be produced at Union Korea Pharm and shipped starting this month.
"Only some normal claims such as trade payables and return provisions remain, so the effective debt-to-equity ratio is about 15%," an official at Bukwang Pharmaceutical said. "We will maximize sales and manufacturing synergies between the two companies to expand both companies' top line and work toward turning Union Korea Pharm profitable."
Bukwang Pharmaceutical (003000) said on the 1st that the Seoul Rehabilitation Court decided on the 31st to terminate the rehabilitation proceedings for Union Korea Pharm under the Debtor Rehabilitation and Bankruptcy Act.
Bukwang Pharmaceutical had paid a total of 30 billion won ($21.6 million) for new shares on May 27, becoming the largest shareholder of Union Korea Pharm. Union Korea Pharm subsequently carried out changes to creditor rights and repayment of rehabilitation claims under its rehabilitation plan. Of about 29.2 billion won in claims due for repayment this year, the company repaid most of the total, excluding some unconfirmed claims. The remaining unpaid balance stands at 76 million won. The company filed for termination of the rehabilitation proceedings with the Seoul Rehabilitation Court on the 14th of last month.
Union Korea Pharm's financial structure has improved significantly since the acquisition. According to Bukwang Pharmaceutical, the company's debt-to-equity ratio has fallen to the 40% range from a state of impaired capital before the acquisition. Past unpaid trade payables, borrowings and bonds with warrants have all been repaid, the company said.
Cooperation between the two companies has already begun. Bukwang Pharmaceutical outsourced drug production to Union Korea Pharm and shipped the digestive medicine Bokhap Pazyme Double Tablet in June. Hardcal Chewable Tablet and Hardcal Chewable Easy Tablet, over-the-counter thyroid and endocrine drugs, will also be produced at Union Korea Pharm and shipped starting this month.
"Only some normal claims such as trade payables and return provisions remain, so the effective debt-to-equity ratio is about 15%," an official at Bukwang Pharmaceutical said. "We will maximize sales and manufacturing synergies between the two companies to expand both companies' top line and work toward turning Union Korea Pharm profitable."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。